Orasis Pharmaceuticals raised $78 million in a Series D round led by Arboretum Ventures and Johnson & Johnson Innovation to support the commercial launch of Qlosi, a novel corrective eye drop for the treatment of presbyopia.

Oct 10, 2024•about 1 year ago

Amount Raised

$78 Million

Round Type

series d

Ponte Vedra BeachTherapeuticsPharmaceuticalBiotechnologyHealth Care

Investors

Maverick VenturesSequoia CapitalSbi (Japan) Innovation FundBluestem CapitalVisionary VenturesFreepoint Capital GroupCatalio Capital ManagementJohnson & Johnson Innovation – Jjdc, Inc.Arboretum Ventures

Description

Orasis Pharmaceuticals announced a $78 million Series D funding round to support the launch of Qlosi, an eye drop designed for presbyopia treatment. The funding included a $68 million equity component and $15 million in structured capital. The investment was backed by notable firms including Arboretum Ventures, Johnson & Johnson Innovation, and several returning investors.

Company Information

Company

Orasis Pharmaceuticals

Location

Ponte Vedra Beach, Florida, United States

About

Orasis Pharmaceuticals developed Qlosi, a corrective eye drop for the treatment of presbyopia in adults. Orasis is led by a collaborative team of industry executives and eye care professionals with a broad range of experiences in research, development, and commercialization of pharmaceutical drugs, as well as finance and business development. Orasis is funded by a diverse group of sophisticated and experienced life science and healthcare investors. Orasis has offices in the United States and Israel.

Related People

6 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends